ClinicalTrials.gg

Program

TAK-360

A development code.

Its studies are mostly in Idiopathic Hypersomnia · Narcolepsy, led by Takeda.

Furthest: phase 3, since Jun 9, 20264 company-led studies, 4 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda44 open or runningphase 3since Jun 9, 2026Feb 3, 2025Nov 30, 2026phase 2 · NCT06952699

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 3, 2025First study: phase 2 study in Idiopathic HypersomniaFirst studyNCT06812078 · 96 planned · United States, France, Hong Kong and more
  2. Apr 23, 2025Phase 2 study in Narcolepsy Type 2NCT06952699 · 88 planned · United States, China, France and more
  3. Jun 2, 2026Phase 2 study in NarcolepsyNCT07633301 · 92 planned · United States, Australia, China and more
  4. Jun 9, 2026Phase 3 study in Idiopathic HypersomniaPhase 3 reachedNCT07646678 · 500 planned · United States, Australia, China and more

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Narcolepsy Type 2NCT06952699
  2. Nov 30, 2026Primary completion: phase 2 study in Idiopathic HypersomniaNCT06812078
  3. Nov 28, 2027Primary completion: phase 2 study in NarcolepsyNCT07633301
  4. Jun 15, 2031Primary completion: phase 3 study in Idiopathic HypersomniaNCT07646678

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07646678Idiopathic Hypersomnia · United States, Australia, China and more3RecruitingJun 15, 2031500
NCT07633301Narcolepsy · United States, Australia, China and more2RecruitingNov 28, 202792
NCT06952699Narcolepsy Type 2 · United States, China, France and more2RecruitingNov 30, 202688
NCT06812078Idiopathic Hypersomnia · United States, France, Hong Kong and more2RecruitingNov 30, 202696

How it is read

Names in the registry

  • “TAK-360”, 4 entries

Codes read as this program: TAK360.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.